BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38795955)

  • 1. Further Evidence of Feasibility, Validity, and Reliability of Quality of Life-Aged Care Consumers: Evidence From Home-Based Care Settings.
    Hutchinson C; Ratcliffe J; Cleland J; Milte R; Muller A; Ly M; Hannaford N; Khadka J
    Value Health; 2024 May; ():. PubMed ID: 38795955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing feasibility, construct validity, and reliability of a new aged care-specific preference-based quality of life instrument: evidence from older Australians in residential aged care.
    Khadka J; Hutchinson C; Milte R; Cleland J; Muller A; Bowes N; Ratcliffe J
    Health Qual Life Outcomes; 2022 Dec; 20(1):159. PubMed ID: 36456953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability of the quality of life-aged care consumers (QOL-ACC) and EQ-5D-5L among older people using aged care services at home.
    Khadka J; Milte R; Hutchinson C; Cleland J; Ratcliffe J
    Health Qual Life Outcomes; 2024 May; 22(1):40. PubMed ID: 38816717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the construct validity of the Quality-of-Life-Aged Care Consumers (QOL-ACC): an aged care-specific quality-of-life measure.
    Khadka J; Ratcliffe J; Hutchinson C; Cleland J; Mulhern B; Lancsar E; Milte R
    Qual Life Res; 2022 Sep; 31(9):2849-2865. PubMed ID: 35680733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression.
    O'Loughlin R; Jones R; Chen G; Mulhern B; Hiscock H; Devlin N; Dalziel K;
    Pharmacoeconomics; 2024 Jun; 42(Suppl 1):57-77. PubMed ID: 38329689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
    Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
    J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis.
    Chuang LH; Cohen AT; Agnelli G; Gumbs PD; Bauersachs R; Kroep S; Gitt AK; Monreal M; Willich SN; van Hout B
    Qual Life Res; 2019 May; 28(5):1155-1177. PubMed ID: 30607785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH; Lang BHH; Yu HMS; Lam CLK
    Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L.
    Martin A; Meads D; Griffiths AW; Surr CA
    Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in HIV/AIDS patients on antiretroviral therapy at a tertiary care facility in Zimbabwe.
    Mafirakureva N; Dzingirai B; Postma MJ; van Hulst M; Khoza S
    AIDS Care; 2016 Jul; 28(7):904-12. PubMed ID: 27098289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction".
    Kouwenberg CAE; Kranenburg LW; Visser MS; Busschbach JJ; Mureau MAM
    J Plast Reconstr Aesthet Surg; 2019 Jan; 72(1):52-61. PubMed ID: 30270015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson's: a systematic review.
    Xin Y; McIntosh E
    Qual Life Res; 2017 Jan; 26(1):1-23. PubMed ID: 27778141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients.
    Pattanaphesaj J; Thavorncharoensap M
    Health Qual Life Outcomes; 2015 Feb; 13():14. PubMed ID: 25890017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.
    Jin X; Al Sayah F; Ohinmaa A; Marshall DA; Smith C; Johnson JA
    Clin Orthop Relat Res; 2019 Jul; 477(7):1632-1644. PubMed ID: 30801280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey.
    Jankowska A; Młyńczak K; Golicki D
    Health Qual Life Outcomes; 2021 May; 19(1):138. PubMed ID: 33952271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study.
    Jones R; O'Loughlin R; Xiong X; Bahrampour M; Devlin N; Hiscock H; Chen G; Mulhern B; Dalziel K;
    Pharmacoeconomics; 2024 Jun; 42(Suppl 1):39-55. PubMed ID: 37955799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany.
    Klapproth CP; Sidey-Gibbons CJ; Valderas JM; Rose M; Fischer F
    Value Health; 2022 May; 25(5):824-834. PubMed ID: 35500951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds.
    van Heusden A; Rivero-Arias O; Herdman M; Hiscock H; Devlin N; Dalziel K;
    Pharmacoeconomics; 2024 Jun; 42(Suppl 1):129-145. PubMed ID: 38238604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
    Yfantopoulos J; Chantzaras A; Kontodimas S
    Arch Dermatol Res; 2017 Jul; 309(5):357-370. PubMed ID: 28528371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.